Login to Your Account



Innovacell Taps Shareholders to Raise $10.7M for Phase III

By Nuala Moran
Staff Writer

Wednesday, May 16, 2012
LONDON – Innovacell Biotechnologie AG raised €8.3 million (US$10.7 million) from existing shareholders as it began a Phase III study of ICES13, its autologous cell therapy for the treatment of stress urinary incontinence.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription